«

»

U.S. Prescription Drug Market Lacks Certain Competitive Features: Case Of Biosimilars

A regularly heard talking point is that follow-on drugs, such as biosimilars and generics, will bring down prices through competition. But, they don’t invariably do so. PBMs may favor more expensive branded products over similar or even bioequivalent versions that are cheaper.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive